

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>6</sup> : C07K 1/107, C12N 15/62</p>	<p>A1</p>	<p>(11) International Publication Number: <b>WO 95/28415</b> (43) International Publication Date: 26 October 1995 (26.10.95)</p>
<p>(21) International Application Number: PCT/SE95/00349 (22) International Filing Date: 31 March 1995 (31.03.95) (30) Priority Data: 9401243-2 13 April 1994 (13.04.94) SE (71) Applicant (for all designated States except US): PHARMACIA AB [SE/SE]; S-171 97 Stockholm (SE). (72) Inventor; and (75) Inventor/Applicant (for US only): PALM, Gunnar [SE/SE]; Skaldevägen 58, S-161 42 Bromma (SE). (74) Agents: TANNERFELDT, Agneta et al.; Pharmacia AB, S-112 87 Stockholm (SE).</p>		<p>(81) Designated States: AU, CA, CZ, FI, JP, KR, NO, NZ, RU, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  Published With international search report.</p>
<p>(54) Title: METHOD OF PROTEIN AND PEPTIDE CLEAVAGE (57) Abstract  In a method of cleaving a protein or peptide in an Asn-Gly bond thereof, the protein or peptide is treated with a compound of the general formula (I): <math>R_1-(CH_2)_n-NH-(CH_2)_m-R_2</math>, wherein <math>R_1</math> is <math>NH_2</math> or <math>OH</math>, <math>R_2</math> is hydrogen, lower alkyl, <math>NH_2</math>, <math>OH</math> or halo, <math>n</math> is an integer from 1 to 3, and <math>m</math> is 0 or an integer from 1 to 3.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

### METHOD OF PROTEIN AND PEPTIDE CLEAVAGE

The present invention relates to the cleavage of proteins and peptides, especially the cleavage of fusion proteins and peptides obtained in recombinant DNA methods.

When producing peptides and proteins in bacteria by recombinant DNA techniques, it is often necessary to produce the peptide or protein fused to a bacterial protein in order to protect the protein or peptide against degradation by proteases, and eventually cleave the fusion product to recover the desired protein or polypeptide. The selection of specific reagents for such cleavage has so far been very limited. One attractive way of cleavage has been the use of hydroxylamine, which cleaves between the amino acids asparagine (Asn) and glycine (Gly).

A drawback with hydroxylamine is, however, that in addition to cleaving the Asn-Gly bond, it also reacts with other asparagine and glutamine residues in the peptide or protein, resulting in the formation of hydroxamates (Canova-Davis, E., et al., (1992) J. Biochem. 285, 207-213). These hydroxamates are difficult to separate from the "native" peptide or protein, and it is also difficult to analyse the content of hydroxamates in a peptide or protein product, since the formation of a hydroxamate of the peptide or protein only represents a mass change of 16 daltons and no change in charge.

The object of the present invention is to provide a cleaving agent which is devoid of the above disadvantages. In accordance with the present inventive concept, such a cleaving agent would, on one hand, like hydroxylamine, act as a nucleophile in the desired cleavage reaction, but would, on the other hand, (i) be heavier than hydroxylamine such that, in the case of side reactions similar to the hydroxamate formation, these side reaction products would be easier to detect, and (ii) carry a charge such that the reaction products would be easier to separate.

According to the present invention, it has been found that specific cleavage of Asn-Gly bonds in proteins and

Germany), 1 mM EDTA, 10 % ethanol, 3 M guanidine-HCl, pH 9.4, at 45 °C for 6 to 18 h.

Analytical HPLC was then performed in the same way as for the hydroxylamine cleavage mixture above and resulted in the same fast eluting peak (Apo fragment 185-243) being obtained.

## EXAMPLE 2

### Cleavage of Insulin-like Growth Factor I

Insulin-like Growth Factor 1, hereinafter IGF-I, was produced in E. coli as a fusion protein Z-IGF-I, where Z is a modified domain of Staphylococcus protein A, essentially as described in Moks, T., et al., (1987) Bio/Technology 5, 379-382. The cleavage site between Z and IGF-I is Asn-Gly, which site was cleaved with (A) hydroxylamine and (B) ethylenediamine as described below.

#### A. hydroxylamine cleavage (comparative)

Cleavage with hydroxylamine of 100 µg of Z-IGF-I was performed under the conditions specified for the corresponding cleavage of Apo in Example 1 above.

After cleavage, IGF-I was purified by desalting to 0.2 M acetic acid on PD10 columns (Pharmacia LKB Biotechnology AB, Sweden).

Desalting was followed by cation exchange on a MonoS column no. 2623 (Pharmacia LKB Biotechnology AB, Sweden). The gradient used was 10-52 % B in A for 20 minutes, where A is: 20 mM ammonium acetate, 10% ethanol, pH 5.4, and B is: 1 M ammonium acetate, 10 % ethanol, pH 5.4.

Analytical HPLC was then performed on a Hewlett Packard 1090 using a YMC-Pack Protein-RP column, PRRP-03-5, C4, 5 µm, 250 x 4.6 mm (YMC Inc., USA) and a gradient of 30-40 % B in A over 40 min. at ambient temperature, where A is: 0.25 % PFP in MilliQ water, and B is: 0.25 % PFP in acetonitrile (HPLC quality). The flow was 1.0 ml/min..

#### B. Ethylenediamine cleavage (method of invention)

100 µg of Z-IGF-I were cleaved with ethylenediamine under the same conditions as those specified for the ethylenediamine cleavage of Apo in Example 1.

Samples were taken after 2, 4 and 6 h and directly analysed, after desalting and cation exchange as described above for the hydroxylamine cleavage of Z-IGF-I, by HPLC on a Beckman System Gold HPLC (Beckman, USA) and a Brownlee  
5 Aquapore Butyl column, 7  $\mu$ m, 220 x 4,6 mm (Applied Biosystems, USA) with a gradient 26-31 % B in A over 30 min. at 50 °C, where A is: 0.25 % PFPA in MilliQ water, and B is: 0.25 % PFPA in acetonitrile (HPLC quality). The flow was 1.0 ml/min..

10 IGF-I was detected after 2 h, and at 4 h the IGF-I peak had increased by about two times. The IGF-I peak at 6 h was about the same size as that for the sample taken at 4 h.

The yield of ethylenediamine cleavage after 4 h was 25  
15 % compared with that obtained in the optimized hydroxylamine cleavage.

Pure IGF-I was added to the 4 h sample, which was then analysed by HPLC. The IGF-I peak increased as assumed.

IGF-I from the ethylenediamine cleavage was isolated  
20 by semipreparative HPLC in the same way as for the analytical HPLC described above. The IGF-I fraction produced was then N-terminal sequenced in five steps by Edman degradation on a solid phase sequencer, Prosequenator 6600 (Millipore, USA). Carboxyl groups on the peptides were  
25 covalently bound to arylamine membrane (Millipore) prior to sequencing. The sequence obtained was identical with that of IGF-I, NH<sub>2</sub>-GlyProGluThrLeu and no additional sequences could be detected.

The molecular weight of the peptides were determined  
30 on a plasma desorption time of flight mass spectrometer, PDMS (Perkin Elmer, USA, BioIon, Sweden) or on an ESR spectrometer (VG Quattro, Fisons, England). The resulting mass spectra gave a single peak at Mw 7646 (theor. Mw 7649). No peak at Mw 7690 was detected which should have  
35 been the case if ethylenediamine had reamidated with asparagine or glutamine.

EXAMPLE 3Cleavage of Z-IGF-I with 2-ethylaminoethylamine

100 µg of the fusion protein Z-IGF-I were cleaved with 2-ethylaminoethylamine (Mw 88.15) under the same conditions as for the ethylenediamine cleavage of Z-IGF-I described in Example 2, except that the reaction temperature was decreased to 34 °C, CAPSO buffer, pH 9.3, (Sigma, USA) was used instead of Tris, and the reaction time was prolonged to 18 h.

Analysis by HPLC on a Hewlett Packard 1090, using a YMC-Pack Protein-RP column, PRRP-03-5, C4, 5 µm, 250 x 4.6 mm (YMC Inc., USA) and a gradient 30-40 % B in A, where A is: 0.25 % PFPA in MilliQ water, and B is: 0.25 % PFPA in acetonitrile (HPLC quality), over 30 min. at ambient temperature and a flow of 1.0 ml/min. indicated a yield of 45 % compared to hydroxylamine cleavage.

At these conditions, the yield of IGF-I, cleaved with ethylenediamine, was 32 % compared to hydroxylamine.

IGF-I from the cleavage reaction was purified via gel filtration, anion exchange and reversed phase HPLC. The mass spectra was identical to that of IGF-I and no peak at 7690 corresponding to reamidation could be detected.


EXAMPLE 4Cleavage of Z-IGF-I with 2-(2-aminoethylamino)ethanol

Cleavage of Z-IGF-I with 2-(2-aminoethylamino)ethanol at the same conditions as in Example 3 gave a yield of 28 % compared to hydroxylamine cleavage. Mass spectra after purification of IGF-I as in Example 3 was identical to that of IGF-I and no reamidation products could be detected.

30

CLAIMS


1. A method of cleaving a protein or peptide in an Asn-Gly bond thereof, characterized by treating the protein or peptide with a compound of the general Formula I:



wherein

- 10  $R_1$  is  $NH_2$  or  $OH$ ,  
 $R_2$  is hydrogen, lower alkyl,  $NH_2$ ,  $OH$  or halo,  
 $n$  is an integer from 1 to 3, and  
 $m$  is 0 or an integer from 1 to 3.
- 15 2. The method of claim 1, characterized in that  $R_1$  is  $NH_2$  and  $R_2$  is hydrogen, methyl,  $NH_2$ ,  $OH$ , fluoro, chloro or bromo.
- 20 3. The method of claim 2, characterized in that the compound of formula I is selected from ethylenediamine, 2-ethylaminoethylamine and 2-(2-aminoethylamino)ethanol.
- 25 4. The method of any one of claims 1 to 3, characterized in that said compound of Formula I is dissolved in a reaction medium.
5. The method of any one of claims 1 to 3, characterized in that said compound of Formula I is immobilized to a solid phase.
- 30 6. The method of any one of claims 1 to 5, characterized in that the cleavage reaction is carried out in an aqueous or aqueous ethanolic medium.
- 35 7. The method of any one of claims 1 to 6, characterized in that said protein is a fusion protein having an Asn-Gly bond in the link between the fusion partners.

8. Use of a compound of the general Formula I:



5

wherein

$R_1$  is  $NH_2$  or  $OH$ ,

$R_2$  is hydrogen, lower alkyl,  $NH_2$ ,  $OH$  or halo,

$n$  is an integer from 1 to 3, and

10  $m$  is 0 or an integer from 1 to 3,

for cleaving proteins and peptides.



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 95/00349

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>		
IPC6: C07K 1/107, C12N 15/62 According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b>		
Minimum documentation searched (classification system followed by classification symbols)		
IPC6: C07K, C12N		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
SE,DK,FI,NO classes as above		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
WPI, WPIL, US PATENTS FULLTEXT DATABASES, MEDLINE, BIOSIS, EMBASE, SCISEARCH, DIALINDEX		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	INT.J.BIOCHEM., Volume 15, No 7, 1983, Kia-Ki Han et al, "Current developments in chemical cleavage of proteins" page 875 - page 884 --	1-8
A	ANALYTICAL BIOCHEMISTRY, Volym 154, 1986, Said Mahboub et al, "Applications of Chemical Cleavage Procedures to the Peptide Mapping of Neurofilament Triplet Protein Bands in Sodium Dodecyl Sulfate-Polyacrylamid Gel Electropho- resis", page 171 - page 182 --	1-8
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
12 July 1995		18.07.95
Name and mailing address of the ISA/ Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. +46 8 666 02 86		Authorized officer Carolina Palmcrantz Telephone No. +46 8 782 25 00

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 95/00349

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>Dialog Information Services, file 155, Medline,  Dialog accession no. 00851695, Medline accession no.  68411695, SAKIYAMA F: "Chemical cleavage of peptide  bonda", Tanpakushitsu Kakusen Koso (Japan) Jan 1968,  13 (1) p 1-10</p> <p>--</p>	1-8
A	<p>Dialog Information Services, file 157, Aidsline,  Dialog accession no. 00003217, Shieh TC et al:  "Purification of Recombinant HIV-TAT Protein from  E Coli (Meeting Abstract)", Faser J; (7):A2252  1990 ISSN 0892-6638</p> <p>--</p>	1-8
A	<p>Dialog Information Services, file 73, Embase,  Dialog accession no. 104771, Embase accession  no. 74106547, Oh S.K. et al: "Peptide bond  hydrolysis by hydroxoquo ethylenediamine  diacetatocobalt(III)</p> <p>--  -----</p>	1-8